SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001654954-21-001050
Filing Date
2021-02-02
Accepted
2021-02-01 21:05:12
Documents
3
Period of Report
2021-01-31
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT gtbp_8k.htm 8-K 31629
2 FORM OF SECOND AMENDMENT AND EXTENSION OF STANDSTILL AND FORBEARANCE AGREEMENT gtbp_ex101.htm EX-10.1 18301
3 FORM OF AMENDMENT TO CONVERTIBLE NOTE, DATED AS OF JANUARY 31, 2021 gtbp_ex10-2.htm EX-10.2 13625
  Complete submission text file 0001654954-21-001050.txt   64993
Mailing Address 9350 WILSHIRE BLVD. SUITE 203 BEVERLY HILLS CA 90212
Business Address 9350 WILSHIRE BLVD. SUITE 203 BEVERLY HILLS CA 90212 (800) 304-9888
GT Biopharma, Inc. (Filer) CIK: 0000109657 (see all company filings)

IRS No.: 941620407 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-08092 | Film No.: 21578627
SIC: 2834 Pharmaceutical Preparations